Study: PIKture-01: First-in-human Study of the PI3KaH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants with Advanced Solid Tumors and as Part of Combination Therapy in Participants with Advanced Breast Cancer
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 5 to 7 business days.
Please understand that:
Thanks again. Volunteers such as yourself are at the core of our work.